1
|
Martvon L, Kotmanova Z, Dobrolubov B, Babalova L, Simera M, Veternik M, Pitts T, Jakus J, Poliacek I. Modulation of Cough Reflex by Gaba-Ergic Inhibition in Medullary Raphé of the Cat. Physiol Res 2020; 69:S151-S161. [PMID: 32228021 DOI: 10.33549/physiolres.934401] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
We studied the effects of GABA receptor agonists microinjections in medullary raphé on the mechanically induced tracheobronchial cough response in anesthetized, unparalyzed, spontaneously breathing cats. The results suggest that GABA-ergic inhibition significantly contributes to the regulation of cough reflex by action of both GABA(A) and GABA(B) receptors. The data are consistent with inhomogeneous occurrence of GABA-ergic neurons in medullary raphé and their different involvement in the cough reflex control. Cells within rostral nucleus raphéobscurus with dominant role of GABA(A) receptors and neurons of rostral nucleus raphépallidus and caudal nucleus raphémagnus with dominant role of GABA(B) receptors participate in regulation of cough expiratory efforts. These cough control elements are distinct from cough gating mechanism. GABA-ergic inhibition in the raphé caudal to obex had insignificant effect on cough. Contradictory findings for GABA, muscimol and baclofen administration in medullary raphé suggest involvement of coordinated activity of GABA on multiple receptors affecting raphé neurons and/or the local neuronal circuits in the raphé modulating cough motor drive.
Collapse
Affiliation(s)
- L Martvon
- Institute of Medical Biophysics, Jessenius Faculty of Medicine in Martin, Comenius University Bratislava, Martin,
| | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Servais L, Shieh P, Dowling J, Kuntz N, Müller-Felber W, Smith B, Bönnemann C, Muntoni F, Bilder D, Duong T, Graham R, Jain M, Lawlor M, MacBean V, Noursalehi M, Pitts T, Rafferty G, Rico S, Prasad S. P.105INCEPTUS pre-phase 1, prospective, non-interventional, natural history run-in study to evaluate subjects aged 4 years and younger with X-linked myotubular myopathy (XLMTM). Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
3
|
Simmons DM, Tse TE, Dailey K, Hartman SJ, Bagsby S, Pitts TM, Tentler JJ, Diamond JR. Abstract P2-06-15: Rational combination of Wee1 and BCL-2 inhibition in preclinical models of triple-negative breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-06-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Triple-negative breast cancer (TNBC) is an aggressive subtype distinguished by its lack of expression of receptors for estrogen, progesterone, and normal human epidermal growth factor 2 expression. TNBC is difficult to treat and is associated with a high risk of recurrence and mortality. In order to effectively treat TNBC, alternative therapeutic targets need to be identified. Wee1 is a tyrosine kinase that phosphorylates CDC2 to pause the cell cycle at the G2 checkpoint as a means to delay mitosis while DNA damage undergoes repair. Inactivation of Wee1 via adavosertib (AZD1775, MK1775), a highly selective inhibitor of Wee1, allows CDC25 to dephosphorylate the CDC2/cyclin B complex resulting in premature initiation of mitosis and, ultimately, mitotic catastrophe and apoptosis. An unbiased screen of adovosertib in combination with other targeted compounds in TNBC patient-derived xenograft (PDX) models demonstrated that the combination of adavosertib and navitoclax, an inhibitor of anti-apoptotic BCL-2 and BCL-XL proteins, had greater efficacy than the single agents alone. The purpose of this study was to investigate the combination of adavosertib and navitoclax in preclinical TNBC models, both in vitro and in vivo.
Methods:
HCC1937, CAL51, MDA-MB-231 and MDA-MB-468 cells were plated in 96-well plates and exposed to increasing concentrations of adavosertib (125nM – 1000nM), navitoclax (2500nM – 10000nM), or the combination. Cellular proliferation was assessed in real-time using IncuCyte Live Cell Analysis, followed by endpoint sulforhodamine B (SRB) assay. Combination effects were analyzed using Calcusyn to determine combination indexes (CI). Apoptosis was assessed via the Caspase 3/7 assay. Western blotting was used to assess changes in expression of CDC2, phospho-CDC2, and BCL2. TNBC PDX models CU_TNBC_013 and CU_TNBC_014 were treated with vehicle, adavosertib (50mg/kg), navitoclax (100mg/kg), or the combination and assessed for tumor growth inhibition.
Results:
The combination of adavosertib and navitoclax resulted in greater antiproliferative effects in vitro compared to either single agent (p< 0.05). This effect was classified as synergistic with CI values <1. We observed a significant increase in apoptosis with the combination treatment as measured by Caspase 3/7 (p <0.005). The combination of adavosertib and navitoclax treatment resulted in a decrease in phospo-CDC2, and BCL2 in cell lines. In vivo, the combination treatment resulted in greater tumor growth inhibition as compared to adavosertib or navitoclax alone in the CU_TNBC_013 and CU_TNBC_014 PDX models.
Conclusions:
The combination of adavosertib and navitoclax is active in preclinical TNBC models and induces apoptosis and tumor growth inhibition. This data supports the continued development of this combination in TNBC with investigation of potential selective markers.
Citation Format: Simmons DM, Tse TE, Dailey K, Hartman SJ, Bagsby S, Pitts TM, Tentler JJ, Diamond JR. Rational combination of Wee1 and BCL-2 inhibition in preclinical models of triple-negative breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-06-15.
Collapse
Affiliation(s)
- DM Simmons
- University of Colorado Cancer Center, Aurora, CO
| | - TE Tse
- University of Colorado Cancer Center, Aurora, CO
| | - K Dailey
- University of Colorado Cancer Center, Aurora, CO
| | - SJ Hartman
- University of Colorado Cancer Center, Aurora, CO
| | - S Bagsby
- University of Colorado Cancer Center, Aurora, CO
| | - TM Pitts
- University of Colorado Cancer Center, Aurora, CO
| | - JJ Tentler
- University of Colorado Cancer Center, Aurora, CO
| | - JR Diamond
- University of Colorado Cancer Center, Aurora, CO
| |
Collapse
|
4
|
Capasso A, Lang J, Pitts TM, Jordan KR, Lieu CH, Davis SL, Diamond JR, Kopetz S, Barbee J, Peterson J, Freed BM, Yacob BW, Bagby SM, Messersmith WA, Slansky JE, Pelanda R, Eckhardt SG. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. J Immunother Cancer 2019; 7:37. [PMID: 30736857 PMCID: PMC6368764 DOI: 10.1186/s40425-019-0518-z] [Citation(s) in RCA: 107] [Impact Index Per Article: 21.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2018] [Accepted: 01/21/2019] [Indexed: 12/13/2022] Open
Abstract
Background The success of agents that reverse T-cell inhibitory signals, such as anti-PD-1/PD-L1 therapies, has reinvigorated cancer immunotherapy research. However, since only a minority of patients respond to single-agent therapies, methods to test the potential anti-tumor activity of rational combination therapies are still needed. Conventional murine xenograft models have been hampered by their immune-compromised status; thus, we developed a hematopoietic humanized mouse model, hu-CB-BRGS, and used it to study anti-tumor human immune responses to triple-negative breast cancer (TNBC) cell line and patient-derived colorectal cancer (CRC) xenografts (PDX). Methods BALB/c-Rag2nullIl2rγnullSIRPαNOD (BRGS) pups were humanized through transplantation of cord blood (CB)-derived CD34+ cells. Mice were evaluated for human chimerism in the blood and assigned into experimental untreated or nivolumab groups based on chimerism. TNBC cell lines or tumor tissue from established CRC PDX models were implanted into both flanks of humanized mice and treatments ensued once tumors reached a volume of ~150mm3. Tumors were measured twice weekly. At end of study, immune organs and tumors were collected for immunological assessment. Results Humanized PDX models were successfully established with a high frequency of tumor engraftment. Humanized mice treated with anti-PD-1 exhibited increased anti-tumor human T-cell responses coupled with decreased Treg and myeloid populations that correlated with tumor growth inhibition. Combination therapies with anti-PD-1 treatment in TNBC-bearing mice reduced tumor growth in multi-drug cohorts. Finally, as observed in human colorectal patients, anti-PD-1 therapy had a strong response to a microsatellite-high CRC PDX that correlated with a higher number of human CD8+ IFNγ+ T cells in the tumor. Conclusion Hu-CB-BRGS mice represent an in vivo model to study immune checkpoint blockade to human tumors. The human immune system in the mice is inherently suppressed, similar to a tumor microenvironment, and thus allows growth of human tumors. However, the suppression can be released by anti-PD-1 therapies and inhibit tumor growth of some tumors. The model offers ample access to lymph and tumor cells for in-depth immunological analysis. The tumor growth inhibition correlates with increased CD8 IFNγ+ tumor infiltrating T cells. These hu-CB-BRGS mice provide a relevant preclinical animal model to facilitate prioritization of hypothesis-driven combination immunotherapies. Electronic supplementary material The online version of this article (10.1186/s40425-019-0518-z) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- A Capasso
- Division of Medical Oncology, School of Medicine, University of Colorado, Anschutz Medical Campus, 13001 E 17th Pl, Aurora, CO, 80045, USA
| | - J Lang
- Department of Immunology and Microbiology, School of Medicine, University of Colorado, Anschutz Medical Campus, 12800 E. 19th Ave P18-8401G, 13001 E 17th Pl, Aurora, CO, 80045, USA.
| | - T M Pitts
- Division of Medical Oncology, School of Medicine, University of Colorado, Anschutz Medical Campus, 13001 E 17th Pl, Aurora, CO, 80045, USA.,University of Colorado Cancer Center, University of Colorado, Anschutz Medical Campus, 1665 Aurora Ct, Aurora, CO, 80045, USA
| | - K R Jordan
- Department of Immunology and Microbiology, School of Medicine, University of Colorado, Anschutz Medical Campus, 12800 E. 19th Ave P18-8401G, 13001 E 17th Pl, Aurora, CO, 80045, USA
| | - C H Lieu
- Division of Medical Oncology, School of Medicine, University of Colorado, Anschutz Medical Campus, 13001 E 17th Pl, Aurora, CO, 80045, USA.,University of Colorado Cancer Center, University of Colorado, Anschutz Medical Campus, 1665 Aurora Ct, Aurora, CO, 80045, USA
| | - S L Davis
- Division of Medical Oncology, School of Medicine, University of Colorado, Anschutz Medical Campus, 13001 E 17th Pl, Aurora, CO, 80045, USA.,University of Colorado Cancer Center, University of Colorado, Anschutz Medical Campus, 1665 Aurora Ct, Aurora, CO, 80045, USA
| | - J R Diamond
- Division of Medical Oncology, School of Medicine, University of Colorado, Anschutz Medical Campus, 13001 E 17th Pl, Aurora, CO, 80045, USA.,University of Colorado Cancer Center, University of Colorado, Anschutz Medical Campus, 1665 Aurora Ct, Aurora, CO, 80045, USA
| | - S Kopetz
- MD Anderson Cancer Center, 1515 Holcombe Blvd10, Houston, TX, 77030, USA
| | - J Barbee
- Department of Immunology and Microbiology, School of Medicine, University of Colorado, Anschutz Medical Campus, 12800 E. 19th Ave P18-8401G, 13001 E 17th Pl, Aurora, CO, 80045, USA
| | - J Peterson
- Department of Immunology and Microbiology, School of Medicine, University of Colorado, Anschutz Medical Campus, 12800 E. 19th Ave P18-8401G, 13001 E 17th Pl, Aurora, CO, 80045, USA
| | - B M Freed
- Division of Allergy and Clinical Immunology, School of Medicine, University of Colorado Denver, 13001 E 17th Pl, Aurora, CO, 80045, USA
| | - B W Yacob
- Division of Medical Oncology, School of Medicine, University of Colorado, Anschutz Medical Campus, 13001 E 17th Pl, Aurora, CO, 80045, USA
| | - S M Bagby
- Division of Medical Oncology, School of Medicine, University of Colorado, Anschutz Medical Campus, 13001 E 17th Pl, Aurora, CO, 80045, USA
| | - W A Messersmith
- Division of Medical Oncology, School of Medicine, University of Colorado, Anschutz Medical Campus, 13001 E 17th Pl, Aurora, CO, 80045, USA.,University of Colorado Cancer Center, University of Colorado, Anschutz Medical Campus, 1665 Aurora Ct, Aurora, CO, 80045, USA
| | - J E Slansky
- University of Colorado Cancer Center, University of Colorado, Anschutz Medical Campus, 1665 Aurora Ct, Aurora, CO, 80045, USA.,Department of Immunology and Microbiology, School of Medicine, University of Colorado, Anschutz Medical Campus, 12800 E. 19th Ave P18-8401G, 13001 E 17th Pl, Aurora, CO, 80045, USA
| | - R Pelanda
- Department of Immunology and Microbiology, School of Medicine, University of Colorado, Anschutz Medical Campus, 12800 E. 19th Ave P18-8401G, 13001 E 17th Pl, Aurora, CO, 80045, USA
| | - S G Eckhardt
- Department of Oncology, Dell Medical School, The University of Texas at Austin, 1701 Trinity Street, Austin, TX, 78712, USA
| |
Collapse
|
5
|
Kotmanova Z, Simera M, Veternik M, Martvon L, Misek J, Jakus J, Shen TY, Musselwhite MN, Pitts T, Bolser DC, Poliacek I. GABA-ergic neurotransmission in the nucleus of the solitary tract modulates cough in the cat. Respir Physiol Neurobiol 2018; 257:100-106. [PMID: 29474953 DOI: 10.1016/j.resp.2018.02.009] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Revised: 01/26/2018] [Accepted: 02/16/2018] [Indexed: 12/27/2022]
Abstract
GABA, muscimol, and baclofen were microinjected into the rostral (rNTS) and caudal solitary tract nucleus (cNTS) in 24 anesthetized cats. Electromyograms (EMGs) of diaphragm (DIA) and abdominal muscles (ABD), blood pressure and esophageal pressure (EP) were recorded and analysed. Bilateral microinjections of 1 mM GABA (total 66 ± 4 nl), 1 mM baclofen (64 ± 4 nl) and unilateral microinjections of 0.5 mM muscimol (33 ± 1 nl) in the rNTS significantly reduced cough number (CN), amplitudes of ABD EMGs, expiratory EP, and prolonged the duration of the cough inspiratory phase. GABA microinjections decreased the amplitudes of cough-related DIA EMGs and inspiratory EP; muscimol microinjections decreased the cough DIA EMG on the contralateral side. Only microinjections of GABA into the cNTS suppressed CN. In some cases, microinjections prolonged the inspiratory phase, lowered respiratory rate, changed the depth of breathing, and increased blood pressure and heart rate. Our results confirm that GABA-ergic inhibitory mechanisms in the rNTS can regulate coughing in the anesthetized cat.
Collapse
Affiliation(s)
- Z Kotmanova
- Institute of Medical Biophysics, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Mala Hora 4, 036 01 Martin, Slovak Republic
| | - M Simera
- Institute of Medical Biophysics, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Mala Hora 4, 036 01 Martin, Slovak Republic.
| | - M Veternik
- Institute of Medical Biophysics, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Mala Hora 4, 036 01 Martin, Slovak Republic
| | - L Martvon
- Institute of Medical Biophysics, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Mala Hora 4, 036 01 Martin, Slovak Republic
| | - J Misek
- Institute of Medical Biophysics, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Mala Hora 4, 036 01 Martin, Slovak Republic
| | - J Jakus
- Institute of Medical Biophysics, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Mala Hora 4, 036 01 Martin, Slovak Republic
| | - T Y Shen
- Dept. of Physiological Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL, USA
| | - M N Musselwhite
- Dept. of Physiological Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL, USA
| | - T Pitts
- Kentucky Spinal Cord Injury Research Center, Department of Neurological Surgery, University of Louisville, Louisville, KY, USA
| | - D C Bolser
- Dept. of Physiological Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL, USA
| | - I Poliacek
- Institute of Medical Biophysics, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Mala Hora 4, 036 01 Martin, Slovak Republic
| |
Collapse
|
6
|
Tentler JJ, Frank JG, Kim DJ, George C, Lee YB, Ely B, Tan AC, Kim J, Pitts TM, Capasso A, Dailey KL, Eckhardt G, Diamond JR. Abstract P5-21-16: Preclinical studies of RX-5902, a beta-catenin modulator in triple negative breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-21-16] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: RX-5902 (Supinoxin) is a novel anti-cancer compound that targets phosphorylated p68 RNA helicase, a member of the DEAD box family of helicases, affecting upstream and downstream molecules in the Wnt canonical pathway. As a single agent, RX-5902 exhibits strong growth inhibition in both in vitro and in vivo settings. Specifically, RX-5902 enhances survival and tumor growth inhibition in numerous xenograft models, including ovarian, renal and breast. We have previously shown RX-5902 inhibits cell growth in a dose-dependent fashion in the triple-negative breast cancer (TNBC) xenograft MDA-MB231. In the current study, we have expanded our investigation of the therapeutic potential of RX-5902 against TNBC using both in vitro and in vivo preclinical models.
Methods: RX-5902 was provided by Rexahn, Inc. (Rockville, MD). Cell proliferation was measured using the Cell-Titer Glo luminescent cell viability assay (Promega). Apoptosis was assessed using Incucyte Caspase 3/7 Green apoptosis assay (Essenbioscience). Immunoblots of MDA-MB-231 cell line were probed for ß-catenin (Cell Signaling). Syngeneic 4T1 murine TNBC mice were obtained from Sippr-BK Laboratory Animal Co (Shanghai, China) and tumor volumes were measured twice a week. When the mean tumor volumes reached ˜90 mm3, mice were randomized and treated with vehicle or RX-5902 PO daily alone or in combination with anti-CTLA4 or anti-PD-1 BIW for 3 weeks. Tumor growth inhibition (TGI) was calculated at Day 25.
Results: A panel of 18 TNBC cell lines were treated with RX-5902 and effects on cell proliferation were measured by the Cell Titer-Glo assay. Using 100nM as a cutoff, 14 sensitive lines and 4 resistant lines were identified, with an average IC50 of 56 nM in the sensitive lines. Of these, we chose 2 sensitive lines (MDA-MB-231, HCC1806) and 2 resistant lines (MDA-MB-436 and CAL-120) and assessed induction of apoptosis by the Incucyte caspase activity assay. Robust induction of apoptosis was observed in both sensitive lines (N=3). These lines were then subjected to cell cycle analysis by flow cytometry, which revealed a pronounced G2/M cell cycle arrest and aneuploidy following exposure to RX-5902. Western blot analysis of the MDA-MB-231 cell line showed decreases in the Wnt pathway-related protein nuclear ß-catenin in doses ranging from 20 nM to 200 nM. Finally, the therapeutic efficacy of RX-5902 was assessed as a single agent and in combination with two immune-oncology agents in the treatment of the TNBC 4T1 animal model. RX-5902 as a single agent showed dose dependency in the 4T1 model, and when given in combination with either anti-CTLA4 or anti-PD1 showed an additive effect (p<0.001). All the treatments were well-tolerated and no severe body weight loss was observed in this study.
Conclusions: RX-5902 showed efficacy against several in vitro and in vivo preclinical models of TNBC. RX-5902 resulted in G2/M arrest and induced apoptosis in sensitive TNBC cell lines and decreases in nuclear beta-catenin. In vivo, RX-5902 demonstrated additive anti-tumor effects when combined with either anti-CTLA4 or anti-PD1 immunotherapies. Together, these finding indicate that RX-5902 may have important clinical implications for the treatment of TNBC. A phase 2a clinical study in metastatic TNBC is ongoing..training_cert
Citation Format: Tentler JJ, Frank JG, Kim DJ, George C, Lee YB, Ely B, Tan AC, Kim J, Pitts TM, Capasso A, Dailey KL, Eckhardt G, Diamond JR. Preclinical studies of RX-5902, a beta-catenin modulator in triple negative breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-21-16.
Collapse
Affiliation(s)
- JJ Tentler
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| | - JG Frank
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| | - DJ Kim
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| | - C George
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| | - YB Lee
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| | - B Ely
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| | - AC Tan
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| | - J Kim
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| | - TM Pitts
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| | - A Capasso
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| | - KL Dailey
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| | - G Eckhardt
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| | - JR Diamond
- University of Colorado School of Medicine, Aurora, CO; Rexahn Pharmaceuticals, Inc., Rockville, MD
| |
Collapse
|
7
|
Diamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson DL, Capasso A, Elias AD, Storniolo AM, Schneider BP, Gao D, Tentler JJ, Borges VF, Miller KD. Abstract PD3-16: Clinical safety and efficacy of the aurora and angiogenic kinase inhibitor ENMD-2076 in previously treated, locally advanced or metastatic triple-negative breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd3-16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype defined by the lack of expression of the estrogen and progesterone receptors and lack of HER2 over-expression. ENMD-2076 is an orally bioavailable small molecule inhibitor of Aurora and angiogenic kinases with pro-apoptotic and antiproliferative activity in preclinical models of TNBC.
Methods: This two institution, single-arm, two-stage, phase II clinical trial enrolled patients with locally advanced or metastatic TNBC refractory to 1-3 prior lines of chemotherapy in the advanced setting. Patients had ECOG PS ≤ 1, measureable disease by RECIST 1.1 and no evidence of brain metastasis. Patients were treated with ENMD-2076 250 mg PO daily with continuous dosing in 4-week cycles until disease progression or unacceptable toxicity occurred. The primary end point was 6-month clinical benefit rate (6-CBR) and secondary endpoints included time to progression (TTP), PK profile, safety and biologic correlatives in archival and fresh serial tumor biopsies in a subset of patients.
Results: Between July 2012 and October 2016, 41 patients were enrolled (median age 54; range 30-73; female 40; male 1). Patients received a mean 1.7 prior lines of chemotherapy for locally advanced unresectable or metastatic disease and 80.5% received prior neoadjuvant or adjuvant chemotherapy (N=33). Thirty-six patients were evaluable per protocol for the primary efficacy analysis. Five patients (12.2%) were not included in the efficacy analysis due to: adverse events (AE) leading to discontinuation prior to objective efficacy assessment (N=3), not meeting eligibility criteria on day 1 (N=1) and withdraw of consent in cycle 1 (N=1). The study proceeded to the second stage of enrollment based on observing three 6-CBR events in Stage 1 (N=18 patients). The 6-CBR in the overall trial was 16.7% (95% exact CI: 6%-32.8%; 2 patients with PR and 4 patients with SD > 6 mos). The median duration of response or clinical benefit in these patients was 32 weeks (8 cycles). 4-CBR was 27.8% (95% exact CI: 14%-45.2%). Dose reduction occurred in 8 patients (20%) for fatigue, hypertension and proteinuria. The most common grade 3 treatment-related adverse events were hypertension (37.5%) and fatigue (10%). One patient experienced grade 4 hypertension. Analysis of serial tumor biopsies prior to and following 2 weeks of ENMD-2076 (N=8 patients), demonstrated a treatment-induced decrease in cellular proliferation (Ki-67) and microvessel density (CD34) as assessed by IHC. Immunofluorescence performed on a subset of samples demonstrated an increase in p53-family member expression following treatment, consistent with changes observed in preclinical TNBC patient-derived tumor xenograft models.
Conclusions: ENMD-2076 has durable clinical activity in a subset of patients with pretreated, advanced or metastatic triple-negative breast cancer. Predictive biomarker development using archival and fresh tumor tissue is underway. Exploration of lower doses of ENMD-2076 in future clinical trials may improve tolerability.
Citation Format: Diamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson DL, Capasso A, Elias AD, Storniolo AM, Schneider BP, Gao D, Tentler JJ, Borges VF, Miller KD. Clinical safety and efficacy of the aurora and angiogenic kinase inhibitor ENMD-2076 in previously treated, locally advanced or metastatic triple-negative breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD3-16.
Collapse
Affiliation(s)
- JR Diamond
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - SG Eckhardt
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - TM Pitts
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - A van Bokhoven
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - D Aisner
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - DL Gustafson
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - A Capasso
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - AD Elias
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - AM Storniolo
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - BP Schneider
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - D Gao
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - JJ Tentler
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - VF Borges
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | - KD Miller
- University of Colorado Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO; The University of Texas at Austin, Livestrong Cancer Institutes, Austin, TX; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| |
Collapse
|
8
|
Wong K, Tan A, Pitts T, Klauck P, Earp S, Frye S, Wang X, Graham D, Eckhardt S. 375 MER as a novel therapeutic target in colorectal cancer. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70501-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
9
|
Diamond JR, Tan AC, Ionkina AA, Newton TP, Pitts TM, Eckhardt SG, Tentler JJ. Abstract P2-09-06: The role of p53 family tumor suppressors in mediating response to aurora kinase inhibition in triple-negative breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p2-09-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype defined by the lack of expression of the estrogen and progesterone receptors and lack of HER2 over-expression. TNBC carries an increased risk of developing distant metastatic disease and cancer-related death. TNBC is heterogeneous in its underlying biology, however, mutations in p53 are found in approximately 80% of tumors. The purpose of this study was to utilize TNBC cell line models to investigate the role of p53 and p73 in mediating sensitivity to MLN8237, a selective Aurora kinase A inhibitor, in the setting of mutant or wildtype p53. Additionally, we used p53 and p73 knock-down models to determine the role of p53 and p73 in mediating induction of apoptosis and cellular senescence in response to Aurora kinase inhibition.
Methods: Eighteen TNBC cell lines were exposed to MLN8237 and the effects on proliferation, apoptosis, and cell cycle distribution were evaluated. Proliferation was assessed using an SRB assay, apoptosis was analyzed using a caspase 3/7 assay and cell cycle was measured using flow cytometry. Proliferation was confirmed using a cell counting technique to control for an increase in cell size following MLN8237 exposure. The p53 wildtype TNBC cell line CAL51 was transduced with several clones of shRNA constructs targeting p53 and p73 with > 80% knockdown by RT-PCR. These clones were exposed to escalating doses of MLN8237 and the effect on proliferation was determined using an SRB assay and the effect on cellular senescence was determined using a senescence associated beta-galactosidase (SA b-gal) assay.
Results: In vitro exposure to MLN8237 resulted in robust inhibition of proliferation in TNBC cell lines which was associated with dose-dependent G2/M cell cycle arrest and induction of caspase-dependent apoptosis in a subset of sensitive cell lines. Knock-down of p53 and p73 in the CAL51 cell line resulted in an increase in the absolute 50% inhibitory concentration (IC50) calculated from the SRB proliferation assay curves from 0.04 μM to > 2 μM, 1.8 μM, > 2 μM and 1.5 μM in the CAL51scr, CAL51p5310, CAL51p5312, CAL51p7326, CAL51p7355, respectively. The sensitive p53 mutated MDA-MB-468 cell line (IC50 40 nM) and the sensitive p53 wild-type CAL51 cell line (IC50 45 nM) were selected for further experimentation. Exposure to MLN8237 at concentrations of 50 nM and 100 nM for 7 days resulted in induction of cellular senescence as detected by the SA b-gal assay in the CAL51 p53 wild-type cell line, but not in the MDA-MB-468 cell line where induction of apoptosis at 48 hours was observed using the caspase 3/7 assay. In the CAL51 p73 knock-down clones, induction of cellular senescence was not observed following exposure to MLN8237.
Conclusions: MLN8237 exhibited robust anticancer activity towards preclinical models of p53 mutated and p53 wild-type TNBC, supporting future clinical investigation of Aurora kinase inhibitors in TNBC. In p53 wild-type TNBC, both p53 and p73 mediate sensitivity to MLN8237 and p73 is essential for induction of cellular senescence following exposure to MLN8237. Biomarkers predictive of response to MLN8237 in p53 mutated TNBC are being developed.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-09-06.
Collapse
Affiliation(s)
- JR Diamond
- University of Colorado Cancer Center, Aurora, CO
| | - AC Tan
- University of Colorado Cancer Center, Aurora, CO
| | - AA Ionkina
- University of Colorado Cancer Center, Aurora, CO
| | - TP Newton
- University of Colorado Cancer Center, Aurora, CO
| | - TM Pitts
- University of Colorado Cancer Center, Aurora, CO
| | - SG Eckhardt
- University of Colorado Cancer Center, Aurora, CO
| | - JJ Tentler
- University of Colorado Cancer Center, Aurora, CO
| |
Collapse
|
10
|
Pitts T, McPhillips K, Selby H, Spreafico A, Bagby S, Britt B, Tentler J, Tan A, Kuida K, Eckhardt S. 562 Antitumor Activity of the Polo-like Kinase (PLK) Inhibitor, TAK-960, Alone and in Combination with Standard Agents Against KRAS WT and MT Colorectal Cancer (CRC) Models. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)72359-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
11
|
Tan A, Britt B, Astling D, Leong S, Lieu C, Tentler J, Pitts T, Arcaroli J, Messersmith W, Eckhardt S. 263 Validation of Preclinical Colorectal Cancer Models Against TCGA Data for Pathway Analysis and Predictive Biomarker Discovery. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)72061-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
12
|
Segers LS, Nuding SC, Vovk A, Pitts T, Baekey DM, O'Connor R, Morris KF, Lindsey BG, Shannon R, Bolser DC. Discharge Identity of Medullary Inspiratory Neurons is Altered during Repetitive Fictive Cough. Front Physiol 2012; 3:223. [PMID: 22754536 PMCID: PMC3386566 DOI: 10.3389/fphys.2012.00223] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2012] [Accepted: 06/03/2012] [Indexed: 11/13/2022] Open
Abstract
This study investigated the stability of the discharge identity of inspiratory decrementing (I-Dec) and augmenting (I-Aug) neurons in the caudal (cVRC) and rostral (rVRC) ventral respiratory column during repetitive fictive cough in the cat. Inspiratory neurons in the cVRC (n = 23) and rVRC (n = 17) were recorded with microelectrodes. Fictive cough was elicited by mechanical stimulation of the intrathoracic trachea. Approximately 43% (10 of 23) of I-Dec neurons shifted to an augmenting discharge pattern during the first cough cycle (C1). By the second cough cycle (C2), half of these returned to a decrementing pattern. Approximately 94% (16 of 17) of I-Aug neurons retained an augmenting pattern during C1 of a multi-cough response episode. Phrenic burst amplitude and inspiratory duration increased during C1, but decreased with each subsequent cough in a series of repetitive coughs. As a step in evaluating the model-driven hypothesis that VRC I-Dec neurons contribute to the augmentation of inspiratory drive during cough via inhibition of VRC tonic expiratory neurons that inhibit premotor inspiratory neurons, cross-correlation analysis was used to assess relationships of tonic expiratory cells with simultaneously recorded inspiratory neurons. Our results suggest that reconfiguration of inspiratory-related sub-networks of the respiratory pattern generator occurs on a cycle-by-cycle basis during repetitive coughing.
Collapse
Affiliation(s)
- L S Segers
- Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida Tampa, FL, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Diamond JR, Eckhardt SG, Tan AC, Selby HM, Newton TP, Pitts TM, Bray MR, Fletcher GC, Tentler JJ. P3-01-08: In Vitro and In Vivo Antitumor Activity of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Triple-Negative Breast Cancer Models. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p3-01-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Triple-negative breast cancer (TNBC) is an aggressive biologic subtype which lacks effective targeted anti-cancer agents and is characterized by a high mitotic index and dependence on angiogenesis. ENMD-2076 is a novel orally bioavailable Aurora and angiogenic kinase inhibitor currently in clinical development with favorable pharmacokinetics and a manageable toxicity profile. The purpose of this study was to use TNBC cell line-based in vitro and in vivo models to demonstrate the antitumor activity of ENMD-2076 towards this breast cancer subtype compared to the luminal and HER2−amplified subtypes. Additionally, we used baseline gene expression profiling and pathway analysis to explore molecular predictors of responsiveness to ENMD-2076 in TNBC.
Methods: Twenty-five breast cancer cell lines were exposed to ENMD-2076 and the effects on proliferation, apoptosis, and cell cycle distribution were evaluated. Proliferation was assessed using an SRB assay, apoptosis was analyzed using a caspase 3/7 assay and cell cycle was measured using flow cytometry. In vitro activity of ENMD-2076 was confirmed in 3-D cell culture and in MDA-MB-231 and MDA-MB-468 triple-negative breast cancer xenograft models and immunohistochemical analysis was performed for phosphor-histone H3 (pHH3). Gene array and gene set enrichment analysis (GSEA) was used to identify pathways differentially regulated in the sensitive and resistance cell lines, including within the triple-negative breast cancer subset.
Results: In vitro exposure to ENMD-2076 resulted in robust inhibition of proliferation in TNBC cell lines which was associated with a G2 cell cycle arrest and induction of caspase-dependent apoptosis. Of the TNBC cell lines screened, 1 of 10 had a mean IC50 value > 5 μmol/L and 7 of 10 had a mean IC50 ≤ 1 μmol/L (Fisher's exact test, p-value = 0.009). In comparison, only 1 luminal (ER+) and one UER2-amplified breast cancer cell line had an IC50 value < 1, whereas 7 and 5 resistant lines were luminal and HER2−amplified, respectively (Fisher's exact test, p-values = 0.02 and 0.11 for ER and HER2 status, respectively). ENMD-2076 exhibited antitumor activity towards MDA-MD-231 and MDA-MB-468 xenograft models of TNBC with statistically significant tumor growth inhibition compared to vehicle control (p< 0.05 and p< 0.01, respectively). A trend towards an increase in pHH3 staining cells in the MDA-MB-231 ENMD-2076 treated group compared to the vehicle control group was observed; however, this was not statistically significant (104.7 ± 36.2 positive cells/mm2 in treated vs. 79.9 ± 34.5 in control). Using significance of analysis of microarrays (SAM) analysis and GSEA, we identified Ran, a member of the mitotic spindle regulation pathway as upregulated in sensitive TNBC cell lines (p = 0.017). Interestingly, AURKA, the main target of ENMD-2076, is a core gene in this pathway.
Conclusions: ENMD-2076 exhibited robust anticancer activity towards preclinical models of TNBC, supporting future clinical investigations of this agent in TNBC with an emphasis on the continued development of biomarkers predictive of response in this breast cancer subset.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-01-08.
Collapse
Affiliation(s)
- JR Diamond
- 1University of Colorado Cancer Center, Aurora, CO; EntreMed, Inc, Toronto, ON, Canada
| | - SG Eckhardt
- 1University of Colorado Cancer Center, Aurora, CO; EntreMed, Inc, Toronto, ON, Canada
| | - AC Tan
- 1University of Colorado Cancer Center, Aurora, CO; EntreMed, Inc, Toronto, ON, Canada
| | - HM Selby
- 1University of Colorado Cancer Center, Aurora, CO; EntreMed, Inc, Toronto, ON, Canada
| | - TP Newton
- 1University of Colorado Cancer Center, Aurora, CO; EntreMed, Inc, Toronto, ON, Canada
| | - TM Pitts
- 1University of Colorado Cancer Center, Aurora, CO; EntreMed, Inc, Toronto, ON, Canada
| | - MR Bray
- 1University of Colorado Cancer Center, Aurora, CO; EntreMed, Inc, Toronto, ON, Canada
| | - GC Fletcher
- 1University of Colorado Cancer Center, Aurora, CO; EntreMed, Inc, Toronto, ON, Canada
| | - JJ Tentler
- 1University of Colorado Cancer Center, Aurora, CO; EntreMed, Inc, Toronto, ON, Canada
| |
Collapse
|
14
|
Pitts T, Rose M, Poliacek I, Sapienza C, Davenport P, Bolser D. Activity Patterns of the Thyropharyngeus (ThPh) Muscle During Eupnoea, Cough and Swallow. Pulm Pharmacol Ther 2011. [DOI: 10.1016/j.pupt.2011.04.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
15
|
Spratlin JL, Pitts TM, Kulikowski GN, Morelli MP, Tentler JJ, Serkova NJ, Eckhardt SG. Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines. Anticancer Res 2011; 31:1093-1103. [PMID: 21508352 PMCID: PMC3866806] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
AIM To determine the phenotypic effects of belinostat (bel) and bortezomib (bor) against pancreatic cancer (PC) and hepatocellular cancer (HCC) cell lines. MATERIALS AND METHODS Antiproliferative effects were assessed using a sulforhodamine B assay. Synergy was evaluated using the Chou and Talalay method. Apoptosis was measured by caspase-3/-7 activity and PARP cleavage. Downstream effector proteins were detected via immunoblotting. Quantitative nuclear magnetic resonance (NMR)-based metabolomics analysis was performed. RESULTS There were single-agent antiproliferative effects against PC and HCC cell lines; the combination of bel and bor (bel+bor) had a synergistic effect. There was up to a 45-fold induction of apoptosis over the control. Post-treatment cell death was associated with p21 up-regulation, more pronounced with treatment with bel+bor. Treatment with bel+bor enhanced hyperacetylation of histone H3 over single-agent bel. A metabolic signature was established for treatments with bor and bel+bor. CONCLUSION The combination of bel+bor displayed significant antiproliferative activity against PC and HCC cell lines, with exhibiting synergistic antiproliferative and proapoptotic patterns even at suboptimal single-agent doses.
Collapse
Affiliation(s)
- J L Spratlin
- Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.
| | | | | | | | | | | | | |
Collapse
|
16
|
Troche MS, Okun MS, Rosenbek JC, Musson N, Fernandez HH, Rodriguez R, Romrell J, Pitts T, Wheeler-Hegland KM, Sapienza CM. Aspiration and swallowing in Parkinson disease and rehabilitation with EMST: a randomized trial. Neurology 2011; 75:1912-9. [PMID: 21098406 DOI: 10.1212/wnl.0b013e3181fef115] [Citation(s) in RCA: 236] [Impact Index Per Article: 18.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE Dysphagia is the main cause of aspiration pneumonia and death in Parkinson disease (PD) with no established restorative behavioral treatment to date. Reduced swallow safety may be related to decreased elevation and excursion of the hyolaryngeal complex. Increased submental muscle force generation has been associated with expiratory muscle strength training (EMST) and subsequent increases in hyolaryngeal complex movement provide a strong rationale for its use as a dysphagia treatment. The current study's objective was to test the treatment outcome of a 4-week device-driven EMST program on swallow safety and define the physiologic mechanisms through measures of swallow timing and hyoid displacement. METHODS This was a randomized, blinded, sham-controlled EMST trial performed at an academic center. Sixty participants with PD completed EMST, 4 weeks, 5 days per week, for 20 minutes per day, using a calibrated or sham, handheld device. Measures of swallow function including judgments of swallow safety (penetration-aspiration [PA] scale scores), swallow timing, and hyoid movement were made from videofluoroscopic images. RESULTS No pretreatment group differences existed. The active treatment (EMST) group demonstrated improved swallow safety compared to the sham group as evidenced by improved PA scores. The EMST group demonstrated improvement of hyolaryngeal function during swallowing, findings not evident for the sham group. CONCLUSIONS EMST may be a restorative treatment for dysphagia in those with PD. The mechanism may be explained by improved hyolaryngeal complex movement. CLASSIFICATION OF EVIDENCE This intervention study provides Class I evidence that swallow safety as defined by PA score improved post EMST.
Collapse
Affiliation(s)
- M S Troche
- PO Box 117420, University of Florida, Gainesville, FL 32611, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Hegland KW, Pitts T, Bolser DC, Davenport PW. Urge to cough with voluntary suppression following mechanical pharyngeal stimulation. BRATISL MED J 2011; 112:109-114. [PMID: 21452760 PMCID: PMC3345525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
OBJECTIVE The goal of this project was to determine if mechanical stimulation to the posterolateral oropharynx would elicit the urge-to-cough and/or cough. BACKGROUND Inhaled agents, such as capsaicin and citric acid, readily produce coughing and the sensation of urge-to-cough. Areas below the glottis are thought to be the primary sensory mediators of these responses, however it is unknown if there are specific areas in the oropharynx or laryngopharynx that are important for the sensation and production of coughing. METHODS Paired-pulse air puffs were delivered to the posterolateral oropharyngeal walls of 11 healthy adults (5 men, 6 women) between the ages of 18 and 30 years. Air puffs were delivered via custom mouthpiece in 4 trials, 50 sets per trial. Instances of cough were recorded, and a modified Borg scale was used to gauge urge-to-cough throughout each trial. RESULTS Instances of cough were recorded in 12/37 trials, and the sensation of an urge-to-cough was present in 25/37 trials. No motor cough response was elicited with an urge-to-cough rating less than 2.4 on the modified Borg scale. A trend towards higher urge-to-cough was noted for later (3rd and 4th) trials. CONCLUSIONS Oropharyngeal mechanical stimulation elicits urge-to-cough and cough in healthy young adults. Like other methods to elicit coughing, the motor and sensory thresholds are different using the oropharyngeal air-puff stimuli. Further, it appears there is a sensitization to the air puff stimuli with later trials associated with stronger urge-to-cough and higher likelihood of coughing versus the first and second trial (Tab. 1, Fig. 5, Ref. 21).
Collapse
Affiliation(s)
- K W Hegland
- Department of Physiological Sciences, University of Florida, Gainesville, Florida 32608, USA.
| | | | | | | |
Collapse
|
18
|
Medeiros BC, Landau HJ, Morrow M, Lockerbie RO, Pitts T, Eckhardt SG. The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines. Leukemia 2007; 21:739-46. [PMID: 17268526 DOI: 10.1038/sj.leu.2404539] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Farnesyl transferase inhibitors (FTIs) target signal-transduction pathways responsible for the proliferation and survival of hematologic malignancies, including acute myelogenous leukemias (AML). Lonafarnib has been shown to be a potent inhibitor of Pgp-mediated drug efflux. On the basis of these findings, we examined the Pgp-inhibitory properties of tipifarnib and assessed its activity when combined with anthracyclines. The effects of tipifarnib on cell proliferation, induction of apoptosis and inhibition of Pgp-mediated anthracycline efflux were analyzed in two human leukemia cell lines overexpressing Pgp (CCRF-CEM and KG1a). Measurement of residual daunorubicin (DNR)-mediated fluorescence after incubation with DNR and tipifarnib demonstrated that tipifarnib significantly inhibited DNR efflux in CCRF-CEM with an IC(50) value less than 0.5 microM. Proliferation and apoptosis assays after exposure to DNR in the presence or absence of tipifarnib demonstrated synergistic inhibition of cellular proliferation, and induction of apoptosis with the combination of tipifarnib and DNR. Similar data was obtained with an enantiomer of tipifarnib that possesses no FTI activity. Incubation with tipifarnib and DNR did not interfere with inhibition of the post-translational processing of HDJ-2. These data suggest that tipifarnib possesses Pgp-inhibitory activity in addition to its FTI activity. In high risk and refractory patients these properties may be exploited as a dual targeting mechanism in the therapy of AML.
Collapse
Affiliation(s)
- B C Medeiros
- Department of Medicine, Division of Medical Oncology, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045, USA
| | | | | | | | | | | |
Collapse
|
19
|
Hill SY, De Bellis MD, Keshavan MS, Lowers L, Shen S, Hall J, Pitts T. Right amygdala volume in adolescent and young adult offspring from families at high risk for developing alcoholism. Biol Psychiatry 2001; 49:894-905. [PMID: 11377407 DOI: 10.1016/s0006-3223(01)01088-5] [Citation(s) in RCA: 163] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND Neurobiological factors have been implicated in the increased susceptibility for developing alcohol dependence that offspring from alcoholic families exhibit. The P300 component of the event-related potential shows developmental changes during childhood and adolescence that appear to be related to risk status. The underlying structural changes that accompany these neurophysiological changes are not well understood. METHODS Magnetic resonance imaging was used to measure cerebral, amygdala, and hippocampal volumes in 17 high-risk adolescent and young adult offspring from multiplex alcoholism families and 17 age-, gender-, and IQ-matched control subjects without a family history for alcoholism or other substance dependence. Twenty-two of the subjects are part of a longitudinal prospective study and have been followed an average of 7.3 years, making it possible to relate P300 developmental trajectories to structural volumes. RESULTS High-risk adolescents and young adults showed reduced right amygdala volume in comparison with control subjects. Right amygdala volume was significantly correlated with visual P300 amplitude. CONCLUSIONS Offspring from families having a high density of alcoholism differ in both neurophysiological and neuroanatomical characteristics that could not be explained by personal drinking history or particular childhood and adolescent psychopathology. Because the amygdala tends to increase in volume during childhood and adolescence, smaller volumes in high-risk children may indicate a developmental delay that parallels delays seen in visual P300 amplitude.
Collapse
Affiliation(s)
- S Y Hill
- Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | | | | | | | | | | | | |
Collapse
|
20
|
Abstract
The ability of Campylobacter jejuni to penetrate normally nonphagocytic host cells is believed to be a key virulence determinant. Recently, kinetics of C. jejuni intracellular survival have been described and indicate that the bacterium can persist and multiply within epithelial cells and macrophages in vitro. Studies conducted by Pesci et al. indicate that superoxide dismutase contributes to intraepithelial cell survival, as isogenic sod mutants are 12-fold more sensitive to intracellular killing than wild-type strains. These findings suggest that bacterial factors that combat reactive oxygen species enable the organism to persist inside host cells. Experiments were conducted to determine the contribution of catalase to C. jejuni intracellular survival. Zymographic analysis indicated that C. jejuni expresses a single catalase enzyme. The gene encoding catalase (katA) was cloned via functional complementation, and an isogenic katA mutant strain was constructed. Kinetic studies indicate that catalase provides resistance to hydrogen peroxide in vitro but does not play a role in intraepithelial cell survival. Catalase does however contribute to intramacrophage survival. Kinetic studies of C. jejuni growth in murine and porcine peritoneal macrophages demonstrated extensive killing of both wild-type and katA mutant strains shortly following internalization. Long-term cultures (72 h postinfection) of infected phagocytes permitted recovery of viable wild-type C. jejuni; in contrast, no viable katA mutant bacteria were recovered. Accordingly, inhibition of macrophage nitric oxide synthase or NADPH oxidase permitted recovery of katA mutant C. jejuni. These observations indicate that catalase is essential for C. jejuni intramacrophage persistence and growth and suggest a novel mechanism of intracellular survival.
Collapse
Affiliation(s)
- W A Day
- Department of Microbiology and Immunology, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814-4799, USA
| | | | | | | |
Collapse
|
21
|
Abstract
In order to begin to compensate for a lack of data on the effects of athletic participation in the development of adolescent mental health patterns, as well as to assess general health of the adolescent population, the Juvenile Wellness and Health Inventory (JWHS-76) was administered to 1,769 high school students. Our results indicate that sports participation is associated with self-reported lower total risk scores, mental and physical health benefits, and an increased risk of injury. This suggests a positive role for organized sports participation in youth populations. Prospective studies are needed to assess the impact of different sports, mounting performance pressure, and transition into collegiate levels of participation.
Collapse
Affiliation(s)
- H Steiner
- Division of Child Psychiatry, Stanford University School of Medicine, CA 94305-5540, USA
| | | | | | | | | |
Collapse
|
22
|
Salmon B, Hallmayer J, Rogers T, Kalaydjieva L, Petersen PB, Nicholas P, Pingree C, McMahon W, Spiker D, Lotspeich L, Kraemer H, McCague P, Dimiceli S, Nouri N, Pitts T, Yang J, Hinds D, Myers RM, Risch N. Absence of linkage and linkage disequilibrium to chromosome 15q11-q13 markers in 139 multiplex families with autism. Am J Med Genet 1999; 88:551-6. [PMID: 10490715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
Chromosomal region 15q11-q13 has been implicated to harbor a susceptibility gene or genes underlying autism. Evidence has been derived from the existence of cytogenetic anomalies in this region associated with autism, and the report of linkage in a modest collection of multiplex families. Most recently, linkage disequilibrium with the marker GABRB3-155CA2 in the candidate locus GABRB3, located in this region, has been reported. We searched for linkage using eight microsatellite markers located in this region of chromosome 15 in 147 affected sib-pairs from 139 multiplex autism families. We also tested for linkage disequilibrium in the same set of families with the same markers. We found no evidence for excess allele sharing (linkage) for the markers in this region. Also, we found no evidence of linkage disequilibrium, including for the locus GABRB3-155CA2. Thus, it appears that the role of this region of chromosome 15 is minor, at best, in the majority of individuals with autism.
Collapse
Affiliation(s)
- B Salmon
- Centre for Clinical Research in Neuropsychiatry, Graylands Hospital/University of Western Australia, Perth, Australia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Risch N, Spiker D, Lotspeich L, Nouri N, Hinds D, Hallmayer J, Kalaydjieva L, McCague P, Dimiceli S, Pitts T, Nguyen L, Yang J, Harper C, Thorpe D, Vermeer S, Young H, Hebert J, Lin A, Ferguson J, Chiotti C, Wiese-Slater S, Rogers T, Salmon B, Nicholas P, Petersen PB, Pingree C, McMahon W, Wong DL, Cavalli-Sforza LL, Kraemer HC, Myers RM. A genomic screen of autism: evidence for a multilocus etiology. Am J Hum Genet 1999; 65:493-507. [PMID: 10417292 PMCID: PMC1377948 DOI: 10.1086/302497] [Citation(s) in RCA: 503] [Impact Index Per Article: 20.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
We have conducted a genome screen of autism, by linkage analysis in an initial set of 90 multiplex sibships, with parents, containing 97 independent affected sib pairs (ASPs), with follow-up in 49 additional multiplex sibships, containing 50 ASPs. In total, 519 markers were genotyped, including 362 for the initial screen, and an additional 157 were genotyped in the follow-up. As a control, we also included in the analysis unaffected sibs, which provided 51 discordant sib pairs (DSPs) for the initial screen and 29 for the follow-up. In the initial phase of the work, we observed increased identity by descent (IBD) in the ASPs (sharing of 51.6%) compared with the DSPs (sharing of 50.8%). The excess sharing in the ASPs could not be attributed to the effect of a small number of loci but, rather, was due to the modest increase in the entire distribution of IBD. These results are most compatible with a model specifying a large number of loci (perhaps >/=15) and are less compatible with models specifying </=10 loci. The largest LOD score obtained in the initial scan was for a marker on chromosome 1p; this region also showed positive sharing in the replication family set, giving a maximum multipoint LOD score of 2.15 for both sets combined. Thus, there may exist a gene of moderate effect in this region. We had only modestly positive or negative linkage evidence in candidate regions identified in other studies. Our results suggest that positional cloning of susceptibility loci by linkage analysis may be a formidable task and that other approaches may be necessary.
Collapse
Affiliation(s)
- N Risch
- Department of Genetics, M322, Stanford University School of Medicine, Stanford, CA 94305-5120, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Steiner H, Pavelski R, Pitts T, McQuivey R. The Juvenile Wellness and Health Survey (JWHS-76): a school based screening instrument for general and mental health in high school students. Child Psychiatry Hum Dev 1998; 29:141-55. [PMID: 9816733 DOI: 10.1023/a:1025088016749] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Existing screening instruments address adolescent health from a pediatric/public health perspective. We developed a school based screening instrument (the JWHS-76) for high schools measuring multiple health related domains from a child psychiatric viewpoint. We studied 1769 students in two suburban high schools (48% girls, mean age 16, predominantly white). Factor analyses revealed five coherent factors: general risk taking, mental health problems, sex related risks, eating and dietary problems, and general health problems. Analyses by gender, age and coping style revealed significant and consistent associations. The JWHS-76 is supported by preliminary evidence as a valid screening instrument in high school.
Collapse
Affiliation(s)
- H Steiner
- Division of Child Psychiatry and Child Development, Stanford University School of Medicine, CA 94305-5710, USA
| | | | | | | |
Collapse
|
25
|
Pitts T, Oxendale R, Kudla K. Extending the provider/vendor relationship. Healthc Inf Manage 1998; 11:57-63. [PMID: 10167389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Affiliation(s)
- T Pitts
- Shared Medical Systems Corporation, USA
| | | | | |
Collapse
|
26
|
Blossom HJ, Pitts T, Huerta VP. Training family practice residents at community health centers. Acad Med 1994; 69:431. [PMID: 8086083 DOI: 10.1097/00001888-199405000-00056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
|
27
|
Pitts T. The illusion of control and the importance of community in health care organizations. Hosp Health Serv Adm 1993; 38:101-9. [PMID: 10127288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
Abstract
The complexity of our health care environment and organizations requires a management style that moves beyond control to empowerment. Even though this complexity minimizes our ability to control events, many organizations are still preoccupied with the illusion of control. This restrains the performance of our health care organizations. Some of the contributing factors supporting this illusion are bureaucracy, scientific methodology, individualism, and our confusion of management with leadership. The concept of "community" is discussed from an organizational perspective. It is suggested that we can improve the performance of our organizations by rediscovering the values of community.
Collapse
Affiliation(s)
- T Pitts
- Department of Family and Community Medicine, University of California at San Franciso, Fresno
| |
Collapse
|